Wolfe Research Reiterates Peerperform Rating on Alnylam Pharmaceuticals (ALNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 161.08 +1.19 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $159.89 | 52 Week High | $109.10 | |||
| Open | $166.73 | 52 Week Low | $31.38 | |||
| Day High | $170.49 | P/E | N/A | |||
| Day Low | $160.29 | EPS | $-1.45 | |||
| Volume | 3,637,695 | |||||
